FOLLOW UP OF THE 1985-86 NHLBI PTCA REGISTRY

在NHLBI经皮腔内治疗中， 冠状动脉成形术（PTCA）登记研究人员，他们是 先锋和最合格的侵入性心脏病专家， 必须对1985-86年队列中的2433名患者进行随访。 临床和血管造影特征以及手术细节 患者和病变水平都经过仔细测量和记录 在这个队列中。 关于临床状态和解剖学变化的数据， 冠状动脉每年更新一次，或每当重复程序， 执行。 1985-86年进行的PTCA技术仍在使用 电流 从那时起，已经进行了改进，但这些都只有 对成功率和并发症发生率的影响极小。 症状性和 解剖学疾病特征与那些 今天接受了经皮腔内冠状动脉成形术 出于这些原因，扩展了随访信息 将与20世纪90年代的治疗决策相关。 一个主要的动机 从搭桥手术中吸取的教训 研究记录了治疗药物丢失的频率增加， 术后5-7年开始起效。 凭借10年的经验和对PTCA评价的奉献精神，我们 协调中心在与 16个登记研究临床研究中心。 随访率保持在95%以上。 科学报告定期分发给各机构，并得到它们的好评。 心脏病学社区 为了与其他经皮 冠状动脉介入治疗的选择，我们最近建立了一个新的注册表， 装置. 在拟议的后续行动结束时， 登记册将能够整合所学到的知识。 目前，预计新设备不会取代 经皮冠状动脉血运重建中的PTCA。 此外，结果 将补充在5年随访中提供的信息 在旁路血管成形术中接受PTCA或CABG治疗的患者 血运重建研究。 到目前为止，登记研究已经确定，PTCA术后4年， 成功扩张患者的死亡率为6%。 三十五 %需要重复血运重建，其中11%采用旁路术 手术 超过75%的患者在PTCA后4年无症状 无论最初的成功。

There is unanimous agreement among the NHLBI Percutaneous Transiluminal Coronary Angioplasty (PTCA) Registry investigators, who are among the pioneers and the best qualified invasive cardiologists, that 10-year follow-up of the 2433 patients in the 1985-86 cohort is imperative. Clinical and angiographic characteristics as well as procedural details on both patient and lesion levels have been carefully measured and documented in this cohort. Data on the clinical status and anatomical changes in the coronaries have been updated annually or whenever repeat procedures were performed. PTCA in 1985-86 was carried out by techniques that are still current. Since then refinements have been made, but these have had only minimal effect on success and complication rates. Symptomatic and anatomical disease characteristics are similar to those of patients who are undergoing PTCA today. For these reasons extended follow-up information will be relevant to therapeutic decisions in the 1990s. A major motivation for the extended follow-up is the lesson learned from bypass surgery studies that documented an increased frequency of loss of therapeutic efficacy beginning 5-7 years after the operation. With 10-years experience and dedication to the evaluation of PTCA our Coordinating Center has an excellent track record in collaboration with the 16 Registry clinical sites. Over 95% follow-up rate has been maintained. Scientific reports are regularly disseminated to, and well received by, the cardiology community. In order to keep abreast with other percutaneous coronary intervention options, we recently established a Registry of new devices. By the end of the proposed follow-up, investigators of both Registries will be in the position to integrate what was learned. Currently, it is not expected that new devices will replace the role of PTCA in percutaneous coronary revascularization. Furthermore, the results will complement those which will become available in the 5-year follow-up of patients treated with PTCA or CABG in the Bypass Angioplasty Revascularization Investigation. Thus far the Registry has established that 4 years after PTCA, the mortality rate was 6% for successfully dilated patients. Thirty-five percent required repeat revascularization of which 11% was with bypass surgery. Over 75% of patients were asymptomatic four years after PTCA regardless of initial success.